daily for at least a year, who had also received courses of systemic corticosteroids in the past (group 2); and 20 patients who were taking both high inhaled corticosteroids and regular low dose prednilone, at a median dose of 7 mg daily (group 3). Vertebral bone density was measured by quantitative computed tomography. Biochemical indices of bone formation and resorption were also measured. Results Mean bone density in group 2 (127-5 (22 6) mg/ml) was similar to that in group 3 (114-5 (36-0) mglml). Bone density was significantly lower in both of these groups than in group 1 (160-4 (27-4) mg/ml). There were no significant differences between groups for any of the markers of Treatment with inhaled topical corticosteroids h jor advance in the treatment of asthm ermitting eetve control ot symptoms without the serious side effct~ssolaeuwith systemic corticsteroids. It has become apparent, however, t4iat inhaled topical corticosteroids may have an adverse effect on bone. in a previous study n patients wirn muT'and moderate asthma taking beclomethasone dipropionate 400 ig daily, or an equivalent dose of inhaled betamethasone, the total calcium content was s?wrrtt be 8&8% lower than in asthmatic patients not taking eimer inhaled or systemic corticosteroids. 4 The efficacy of inhaled corticosteroids in treating asthma is dose dependent so that by increasing the dosage patients with more severe asthma can be kept in remission. 5 The aim of the present study was to investigate trabecular bone density in patients taking high dose inhaled beclomethasone dipropionate.
Methods

PATIENTS
We studied 57 The 20 patients in group 3 were attending hospital clinics with asthma and needed daily oral prednisolone in a median dosage of 7 (range 5-30) mg, which they had been taking for a median of 8 (range 1-25) years. They had also intermittently required courses of high dose systemic corticosteroids, and had taken regular high dose inhaled topical corticosteroids for a median of five (range 1-7) years.
Informed consent was obtained from all patients and approval for the study was given by the local ethical committee.
BONE METABOLISM AND DENSITY
Indices of bone metabolism were measured in all patients. A morning sample of serum was collected for measurement of serum calcium, total alkaline phosphatase, and osteocalcin.6 The latter two are markers of bone formation. A fasting urine sample was analysed for pyridinoline and deoxypyridinoline cross links7; both give a measure of collagen breakdown, the latter being a more specific index for collagen breakdown in bone.8 Trabecular bone density was measured by quantitative single energy computed tomography of the lumbar spine.9 The average value for bone density of lumbar vertebrae Li-3 was calculated and expressed in mg/ml. These average values were also expressed as standard deviations above or below the predicted mean value (derived from values for a normal populationl'). The precision of the technique was assessed by performing duplicate measurements on 10 normal subjects, which gave a coefficient of variation of 0-98%. Bone density evaluation and the measurement of indices of bone turnover in serum and urine were carried out without knowledge of the group to which the patient belonged.
ACTIVITY OF PATIENTS
Patients' level of activity at work and during recreation was assessed by means of a simple scale of hours of activity per week, where activity was defined as anything that more than doubled the basal metabolic rate (grade 1-less than 1 hour; grade 2-1-3 hours; grade 3-3-6 hours; grade 4-more than 6 hours." ANALYSIS Differences between groups were compared by using Student's t test for normally distributed data and the Mann-Whitney U test for nonparametric data. The association between bone density and the duration of steroid treatment was assessed by regression analysis.
Results
Bone density, indices of bone turnover, FEV1 and the level of activity for the patients in the three groups are shown in table 2. Mean bone densities were significantly lower in groups 2 and 3 (p < 0-001) than in group 1; there was no difference between groups 2 and 3. Bone density results are also shown in the figure, expressed in terms of standard deviation above or below the predicted normal values for subjects of the same age and sex.
Mean FEV, was significantly lower (p < 0-05) in group 2 than in group 1, and lower in group 3 than in group 1 (p < 0 05). The level of activity at work and during recreation was similar across the three groups.
Among the 20 patients in group 2 there was no difference in bone density between the 10 patients who had received oral corticosteroids during the past year and the 10 patients who had not (figure). Similarly, there was no difference between the 12 patients who were taking their inhaled corticosteroids through a spacer device and those who were not. There was no relation between the duration of treatment with high dose inhaled corticosteroids and bone density.
Serum calcium and total alkaline phosphatase, serum osteocalcin, and urinary pyridinium cross links were similar in the three groups of patients.
All patients with bone densities more than two SD below the predicted values were referred to a clinic specialising in the treatment of osteopenia and osteoporosis. breakdown (increased urinary hydroxy creatinine ratio) and a reduction i formation (reduced serum alkaline phatase).'" Pouw et al studied eight subjects who also took beclomethasone a day for two weeks: osteocalcin concen fell significantly during the treatment p' fully recovered one week after the methasone was stopped.'4 Teelucksin found a fall in osteocalcin concen in healthy subjects taking beclometh: daily doses of 400-2000 pg; the magnitude of * the fall was dose dependent. '5 In the present study indices of bone turnover, including osteocalcin concentration, were the same in all three groups, implying that bone loss had occurred at some time in the past. This may have occurred when patients were initially * started on high dose beclomethasone; after some months bone formation and bone breakdown could have returned to pretreatment j levels, but because there was no compensatory increase in bone formation or reduction in bone loss bone density remained low. In patients * taking systemic corticosteroids bone loss is most rapid during the first few months of treatment 
